318 related articles for article (PubMed ID: 37507218)
1. Targeting MS4A4A on tumour-associated macrophages restores CD8+ T-cell-mediated antitumour immunity.
Li Y; Shen Z; Chai Z; Zhan Y; Zhang Y; Liu Z; Liu Y; Li Z; Lin M; Zhang Z; Liu W; Guan S; Zhang J; Qian J; Ding Y; Li G; Fang Y; Deng H
Gut; 2023 Nov; 72(12):2307-2320. PubMed ID: 37507218
[TBL] [Abstract][Full Text] [Related]
2. TREM2
Tan J; Fan W; Liu T; Zhu B; Liu Y; Wang S; Wu J; Liu J; Zou F; Wei J; Liu L; Zhang X; Zhuang J; Wang Y; Lin H; Huang X; Chen S; Kuang M; Li J
J Hepatol; 2023 Jul; 79(1):126-140. PubMed ID: 36889359
[TBL] [Abstract][Full Text] [Related]
3. Targeting cancer-associated fibroblast-secreted WNT2 restores dendritic cell-mediated antitumour immunity.
Huang TX; Tan XY; Huang HS; Li YT; Liu BL; Liu KS; Chen X; Chen Z; Guan XY; Zou C; Fu L
Gut; 2022 Feb; 71(2):333-344. PubMed ID: 33692094
[TBL] [Abstract][Full Text] [Related]
4. Blocking LTB
Yan J; Zhu J; Li X; Yang R; Xiao W; Huang C; Zheng C
Phytomedicine; 2023 Oct; 119():154968. PubMed ID: 37531900
[TBL] [Abstract][Full Text] [Related]
5. Blockade of V-domain immunoglobulin suppressor of T-cell activation reprograms tumour-associated macrophages and improves efficacy of PD-1 inhibitor in gastric cancer.
Cao Y; Yu K; Zhang Z; Gu Y; Gu Y; Li W; Zhang W; Shen Z; Xu J; Qin J
Clin Transl Med; 2024 Feb; 14(2):e1578. PubMed ID: 38356419
[TBL] [Abstract][Full Text] [Related]
6. PI3Kγδ inhibitor plus radiation enhances the antitumour immune effect of PD-1 blockade in syngenic murine breast cancer and humanised patient-derived xenograft model.
Han MG; Jang BS; Kang MH; Na D; Kim IA
Eur J Cancer; 2021 Nov; 157():450-463. PubMed ID: 34601286
[TBL] [Abstract][Full Text] [Related]
7. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
[TBL] [Abstract][Full Text] [Related]
8. GM-CSF drives myelopoiesis, recruitment and polarisation of tumour-associated macrophages in cholangiocarcinoma and systemic blockade facilitates antitumour immunity.
Ruffolo LI; Jackson KM; Kuhlers PC; Dale BS; Figueroa Guilliani NM; Ullman NA; Burchard PR; Qin SS; Juviler PG; Keilson JM; Morrison AB; Georger M; Jewell R; Calvi LM; Nywening TM; O'Dell MR; Hezel AF; De Las Casas L; Lesinski GB; Yeh JJ; Hernandez-Alejandro R; Belt BA; Linehan DC
Gut; 2022 Jul; 71(7):1386-1398. PubMed ID: 34413131
[TBL] [Abstract][Full Text] [Related]
9. High baseline tumor burden-associated macrophages promote an immunosuppressive microenvironment and reduce the efficacy of immune checkpoint inhibitors through the IGFBP2-STAT3-PD-L1 pathway.
Wen Z; Sun H; Zhang Z; Zheng Y; Zheng S; Bin J; Liao Y; Shi M; Zhou R; Liao W
Cancer Commun (Lond); 2023 May; 43(5):562-581. PubMed ID: 37031362
[TBL] [Abstract][Full Text] [Related]
10. Delicaflavone reactivates anti-tumor immune responses by abrogating monocytic myeloid cell-mediated immunosuppression.
Li L; You W; Wang X; Zou Y; Yao H; Lan H; Lin X; Zhang Q; Chen B
Phytomedicine; 2023 Jan; 108():154508. PubMed ID: 36332384
[TBL] [Abstract][Full Text] [Related]
11. USP7 targeting modulates anti-tumor immune response by reprogramming Tumor-associated Macrophages in Lung Cancer.
Dai X; Lu L; Deng S; Meng J; Wan C; Huang J; Sun Y; Hu Y; Wu B; Wu G; Lovell JF; Jin H; Yang K
Theranostics; 2020; 10(20):9332-9347. PubMed ID: 32802195
[No Abstract] [Full Text] [Related]
12. Complement receptor C5aR1 blockade reprograms tumor-associated macrophages and synergizes with anti-PD-1 therapy in gastric cancer.
Zhang P; Gu Y; Wang J; Lv K; Lin C; Zhang H; Li H; He H; Li R; Liu H; Xu J
Int J Cancer; 2023 Jul; 153(1):224-237. PubMed ID: 36799619
[TBL] [Abstract][Full Text] [Related]
13. CSF1R inhibition reprograms tumor-associated macrophages to potentiate anti-PD-1 therapy efficacy against colorectal cancer.
Lv Q; Zhang Y; Gao W; Wang J; Hu Y; Yang H; Xie Y; Lv Y; Zhang H; Wu D; Hu L; Wang J
Pharmacol Res; 2024 Apr; 202():107126. PubMed ID: 38432446
[TBL] [Abstract][Full Text] [Related]
14. Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma.
Li X; Yao W; Yuan Y; Chen P; Li B; Li J; Chu R; Song H; Xie D; Jiang X; Wang H
Gut; 2017 Jan; 66(1):157-167. PubMed ID: 26452628
[TBL] [Abstract][Full Text] [Related]
15. Progranulin induces immune escape in breast cancer via up-regulating PD-L1 expression on tumor-associated macrophages (TAMs) and promoting CD8
Fang W; Zhou T; Shi H; Yao M; Zhang D; Qian H; Zeng Q; Wang Y; Jin F; Chai C; Chen T
J Exp Clin Cancer Res; 2021 Jan; 40(1):4. PubMed ID: 33390170
[TBL] [Abstract][Full Text] [Related]
16. Ponatinib delays the growth of solid tumours by remodelling immunosuppressive tumour microenvironment through the inhibition of induced PD-L1 expression.
Barnwal A; Tamang R; Sanjeev Das ; Bhattacharyya J
Br J Cancer; 2023 Oct; 129(6):1007-1021. PubMed ID: 37400678
[TBL] [Abstract][Full Text] [Related]
17. Targeting myeloid checkpoint Siglec-10 reactivates antitumor immunity and improves anti-programmed cell death 1 efficacy in gastric cancer.
Lv K; Sun M; Fang H; Wang J; Lin C; Liu H; Zhang H; Li H; He H; Gu Y; Li R; Shao F; Xu J
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37935567
[TBL] [Abstract][Full Text] [Related]
18. M2 subtype tumor associated macrophages (M2-TAMs) infiltration predicts poor response rate of immune checkpoint inhibitors treatment for prostate cancer.
JiaWei Z; ChunXia D; CunDong L; Yang L; JianKun Y; HaiFeng D; Cheng Y; ZhiPeng H; HongYi W; DeYing L; ZhiJian L; Xiao X; QiZhao Z; KangYi X; WenBing G; Ming X; JunHao Z; JiMing B; ShanChao Z; MingKun C
Ann Med; 2021 Dec; 53(1):730-740. PubMed ID: 34032524
[TBL] [Abstract][Full Text] [Related]
19. Modulation of miR-146b by N6-methyladenosine modification remodels tumor-associated macrophages and enhances anti-PD-1 therapy in colorectal cancer.
He S; Song W; Cui S; Li J; Jiang Y; Chen X; Peng L
Cell Oncol (Dordr); 2023 Dec; 46(6):1731-1746. PubMed ID: 37402945
[TBL] [Abstract][Full Text] [Related]
20. Siglec-9
Wang Y; He M; Zhang C; Cao K; Zhang G; Yang M; Huang Y; Jiang W; Liu H
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37709296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
